Close Menu

NEW YORK ─ ContextVision said Monday that it has been granted CE marking for its Inify Prostate Screening digital pathology product, making it available for routine clinical use in the European Union.

Stockholm-based ContextVision said its Inify Prostate Screening artificial intelligence-based software predicts, outlines, and quantifies suspected cancerous areas in a series of prostate biopsies. It presorts slides in a worst-first order, allowing pathologists to work immediately on the most relevant areas.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.